Ingavirin 60 mg capsules 10

Size chart
Women's clothing size
Euro 32/34 36 38 40
USA 0/2 4 6 8
Bust(in) 31-32 33 34 36
Bust(cm) 80.5-82.5 84.5 87 92
Waist(in) 24-25 26 27 29
Waist(cm) 62.5-64.5 66.5 69 74
Hips(in) 34-35 36 37 39
Hips(cm) 87.5-89.5 91.5 94 99
How To Measure Your Bust

With your arms relaxed at your sides, measure around the fullest part of your chest.

How To Measure Your Waist

Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.

Volume discounts

Quantity Unit discount You Save
2 19% $13.57
3 22% $23.56
4 28% $39.98
 Customer ratings and reviews
Nobody has posted a review yet
in this language
Add to compare0
Add to wishlist



Imidazolylethanamide pentanedioic acid


60 mg.


Active substance: imidazolylethanamide pentanedioic acid (vitaglutam) in terms of 100% substance - 60.00 mg;

Excipients: lactose monohydrate, potato starch, silicon dioxide colloidal (aerosil), magnesium stearate; hard gelatin capsules: titanium dioxide E 171, iron oxide yellow dye E 172, gelatin;

Composition of ink for the logo: shellac, propylene glycol E 1520, titanium dioxide E 171.

Pharmacological properties

Antiviral drug.

In preclinical and clinical studies, efficacy has been shown against influenza viruses of type A (A / H1N1, including "swine" A / H1N1 pdm09, A / H3N2), A / H5N1) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enteroviruses, including Coxsackie virus and rhinovirus.

Contributes to the accelerated elimination of viruses, reducing the duration of the disease, reducing the risk of complications.

The mechanism of action is realized at the level of infected cells by stimulating the factors of innate immunity suppressed by viral proteins. In experimental studies, in particular, it was shown that the drug Ingavirin ® increases the expression of the interferon receptor of the first type IFNAR on the surface of epithelial and immunocompetent cells. An increase in the density of interferon receptors leads to an increase in the sensitivity of cells to endogenous interferon signals. The process is accompanied by activation (phosphorylation) of the transmitter protein STAT1, which transmits a signal to the cell nucleus to induce antiviral genes. It is shown that in conditions of infection, the drug stimulates the production of antiviral effector protein MxA, which inhibits intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication.

The drug causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced α-interferon producing ability of blood leukocytes, stimulates the γ-interferon producing ability of leukocytes. It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells with high killer activity against virus-infected cells.

The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-α), interleukins (IL-1β and IL-6)), a decrease in the activity of myeloperoxidase.

In experimental studies, it has been shown that co-administration with antibiotics increases the effectiveness of therapy on a model of bacterial sepsis, incl. caused by penicillin-resistant strains of staphylococcus.

Spent experimental toxicological studies indicate a low level of toxicity and a high safety profile of the drug.

Indications for use
  • Treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection, rhinovirus infection) in children from 7 to 17 years.
  • Prevention of influenza A and B and other acute respiratory viral infections in children from 7 to 17 years.
  • Hypersensitivity to the active substance or any other component of the drug.
  • Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
  • Pregnancy.
  • Period of breastfeeding.
  • Children's age up to 7 years.
  • This dosage form is not intended for use in persons 18 years of age and older (necessary the use of dosage forms that provide the possibility of taking the drug Ingavirin® at a dose of 90 mg).
Use in pregnancy and lactation

The use of the drug during pregnancy has not been studied. The use of the drug during lactation has not been studied, therefore, if necessary, the use of the drug during lactation should stop breastfeeding.

Special instructions

Simultaneous administration of other antiviral drugs without first consulting a doctor is not recommended.

Save the instruction. It may be needed again. If you have any questions, please contact your doctor.

Influence on the ability to drive vehicles, mechanisms

It has not been studied, however, given the mechanism of action and the profile of adverse reactions, it can be assumed that the drug does not affect the ability to drive vehicles, mechanisms.

Usage and doses

Inwards. Regardless of food intake.

In children from 3 to 6 years of age who have difficulty swallowing the capsule, dilution of the contents of the capsule in water or apple juice is allowed. To do this, carefully open the capsule over a container with a small amount (50-70 ml) of boiled water or apple juice at room temperature, pour the contents of the capsule into water or juice, stir the mixture for 20 seconds and drink it whole. Added sugar is allowed. The mixture should be prepared immediately before taking; the finished mixture is not subject to storage.

For the treatment and prevention of influenza and acute respiratory viral infections, adults are prescribed 90 mg 1 time per day, children from 7 years old - 60 mg 1 time per day, children from 3 to 6 years old - 30 mg 1 time per day.

The duration of treatment of influenza and acute respiratory viral infections in adults and children from 7 years - 5-7 days (depending on the severity of the condition). Duration of treatment for influenza and acute respiratory viral infections in children from 3 to 6 years - 5 days. Reception of the drug begins from the moment the first symptoms of the disease appear, preferably no later than 2 days from the onset of the disease.

Adults and children with severe symptoms, as well as in the presence of concomitant diseases (diseases of the respiratory and cardiovascular systems, diabetes mellitus, obesity), should take a double dose of the drug in the first three days of the disease, then continue taking in the usual dosage for 2-4 days.

For the prevention of influenza and acute respiratory viral infections after contact with sick persons, adults and children from 7 years of age, the drug is prescribed for 7 days, for children from 3 to 6 years - for 5 days.

If after 5 days of treatment there is no improvement or the symptoms worsen, or new symptoms appear, it is necessary to consult a doctor. Use the drug only according to the indications, the method of use and in those doses specified in How to.

Side effects

Allergic reactions (rarely).

If any of the side effects listed in the instructions are aggravated or you notice any other side effects not listed in the instructions, tell your doctor.

Storage conditions

In a dry place, protected from light and out of the reach of children at a temperature not exceeding 25 ° C.

Shelf life 3 years.

Conditions of release from pharmacies

No prescription.

Read more
Product Details

Data sheet

Dosage form
60 mg
Imidazolylethanamide pentanedioic acid
Number of tablets
INN Russian
Имидазолилэтанамид пентандиовой кислоты
Russian title
No comments

Be the first to write your review !



Create a free account to save loved items.

Sign in

Create a free account to use wishlists.

Sign in